We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App





Next Generation SARS-CoV-2 Test Measures Response to COVID-19 Vaccine and Neutralizing Antibody Levels in 10 Minutes

By HospiMedica International staff writers
Posted on 13 Oct 2021
Print article
Illustration
Illustration

The second generation version of a rapid neutralizing antibody test for COVID-19 will not only show if the users have responded to their COVID-19 vaccine but also perform a semi-quantitative analysis of their neutralizing antibody levels in a single test.

AXIM Biotechnologies, Inc. (San Diego, CA, USA) is developing the second generation version of its original rapid test (currently under FDA review) that measures the levels of neutralizing antibodies, which provide protection from COVID-19 infection if blood levels are high enough. Although both antibodies and T cells are both involved in protection from COVID-19, antiviral T cell responses are technically and logistically difficult to measure. Unlike T cells, antiviral antibodies are relatively easy to detect and measure from a finger-stick drop of blood.

The purpose of a vaccine is to induce antibodies against SARS-CoV-2 virus to prevent infection but unfortunately, not all of these antibodies neutralize the virus and protect the vaccine recipient. AXIM has developed the second generation version of its original test which differentiates antibodies that simply bind to the virus but do not neutralize it versus antibodies that bind and neutralize the virus. This is an important distinction because COVID-19 vaccines do not induce high levels of neutralizing antibodies in all recipients. AXIM’s second generation test provides users with a test that shows if they responded to their COVID-19 vaccine and a semi-quantitative analysis of their neutralizing antibody levels in a single test.

“This new test is extremely important because it helps people know if they are protected after receiving the vaccine in just 10-minutes,” said John W. Huemoeller II, AXIM Biotech Chief Executive Officer. “People want to make sure they are protected as vaccine immunity wanes so that they don’t develop an asymptomatic infection and transmit the virus to vulnerable populations.”

Related Links:
AXIM Biotechnologies, Inc. 

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
12-Channel ECG
CM1200B
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Digital Radiography Generator
meX+20BT lite

Print article

Channels

Surgical Techniques

view channel
Image: Miniaturized electric generators based on hydrogels for use in biomedical devices (Photo courtesy of HKU)

Hydrogel-Based Miniaturized Electric Generators to Power Biomedical Devices

The development of engineered devices that can harvest and convert the mechanical motion of the human body into electricity is essential for powering bioelectronic devices. This mechanoelectrical energy... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.